Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?

Classical Hodgkin lymphoma (HL) patients achieve excellent outcomes; therefore, treatment de‐escalation strategies to spare toxicity have been prioritized. In a large randomized trial of early‐stage HL patients, omission of chemotherapeutic agents including bleomycin from the standard ABVD (doxorubi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunther, Jillian R., Pinnix, Chelsea C., Glober, Gordon R., Christopherson, Kaitlin M., Fang, Penny, Lee, Hun Ju, Ahmed, Sairah, Steiner, Raphael E., Nair, Ranjit, Strati, Paolo, Neelapu, Sattva S., Nastoupil, Loretta J., Dabaja, Bouthaina S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455016/
https://www.ncbi.nlm.nih.gov/pubmed/32864660
http://dx.doi.org/10.1002/jha2.1
_version_ 1783575550349017088
author Gunther, Jillian R.
Pinnix, Chelsea C.
Glober, Gordon R.
Christopherson, Kaitlin M.
Fang, Penny
Lee, Hun Ju
Ahmed, Sairah
Steiner, Raphael E.
Nair, Ranjit
Strati, Paolo
Neelapu, Sattva S.
Nastoupil, Loretta J.
Dabaja, Bouthaina S.
author_facet Gunther, Jillian R.
Pinnix, Chelsea C.
Glober, Gordon R.
Christopherson, Kaitlin M.
Fang, Penny
Lee, Hun Ju
Ahmed, Sairah
Steiner, Raphael E.
Nair, Ranjit
Strati, Paolo
Neelapu, Sattva S.
Nastoupil, Loretta J.
Dabaja, Bouthaina S.
author_sort Gunther, Jillian R.
collection PubMed
description Classical Hodgkin lymphoma (HL) patients achieve excellent outcomes; therefore, treatment de‐escalation strategies to spare toxicity have been prioritized. In a large randomized trial of early‐stage HL patients, omission of chemotherapeutic agents including bleomycin from the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen was not found to be noninferior; however, the effect of partial omission is unknown. We investigated the effect of bleomycin omission on outcome for 150 early‐stage HL patients. At 8 years, freedom from relapse was 99% for both patients who received complete or incomplete bleomycin, which is reassuring for patients requiring bleomycin omission due to toxicity.
format Online
Article
Text
id pubmed-7455016
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74550162021-07-01 Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes? Gunther, Jillian R. Pinnix, Chelsea C. Glober, Gordon R. Christopherson, Kaitlin M. Fang, Penny Lee, Hun Ju Ahmed, Sairah Steiner, Raphael E. Nair, Ranjit Strati, Paolo Neelapu, Sattva S. Nastoupil, Loretta J. Dabaja, Bouthaina S. EJHaem Short Reports Classical Hodgkin lymphoma (HL) patients achieve excellent outcomes; therefore, treatment de‐escalation strategies to spare toxicity have been prioritized. In a large randomized trial of early‐stage HL patients, omission of chemotherapeutic agents including bleomycin from the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen was not found to be noninferior; however, the effect of partial omission is unknown. We investigated the effect of bleomycin omission on outcome for 150 early‐stage HL patients. At 8 years, freedom from relapse was 99% for both patients who received complete or incomplete bleomycin, which is reassuring for patients requiring bleomycin omission due to toxicity. John Wiley and Sons Inc. 2020-02-07 /pmc/articles/PMC7455016/ /pubmed/32864660 http://dx.doi.org/10.1002/jha2.1 Text en © 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Reports
Gunther, Jillian R.
Pinnix, Chelsea C.
Glober, Gordon R.
Christopherson, Kaitlin M.
Fang, Penny
Lee, Hun Ju
Ahmed, Sairah
Steiner, Raphael E.
Nair, Ranjit
Strati, Paolo
Neelapu, Sattva S.
Nastoupil, Loretta J.
Dabaja, Bouthaina S.
Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
title Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
title_full Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
title_fullStr Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
title_full_unstemmed Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
title_short Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
title_sort partial omission of bleomycin for early‐stage hodgkin lymphoma patients treated with combined modality therapy: does incomplete abvd lead to inferior outcomes?
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455016/
https://www.ncbi.nlm.nih.gov/pubmed/32864660
http://dx.doi.org/10.1002/jha2.1
work_keys_str_mv AT guntherjillianr partialomissionofbleomycinforearlystagehodgkinlymphomapatientstreatedwithcombinedmodalitytherapydoesincompleteabvdleadtoinferioroutcomes
AT pinnixchelseac partialomissionofbleomycinforearlystagehodgkinlymphomapatientstreatedwithcombinedmodalitytherapydoesincompleteabvdleadtoinferioroutcomes
AT globergordonr partialomissionofbleomycinforearlystagehodgkinlymphomapatientstreatedwithcombinedmodalitytherapydoesincompleteabvdleadtoinferioroutcomes
AT christophersonkaitlinm partialomissionofbleomycinforearlystagehodgkinlymphomapatientstreatedwithcombinedmodalitytherapydoesincompleteabvdleadtoinferioroutcomes
AT fangpenny partialomissionofbleomycinforearlystagehodgkinlymphomapatientstreatedwithcombinedmodalitytherapydoesincompleteabvdleadtoinferioroutcomes
AT leehunju partialomissionofbleomycinforearlystagehodgkinlymphomapatientstreatedwithcombinedmodalitytherapydoesincompleteabvdleadtoinferioroutcomes
AT ahmedsairah partialomissionofbleomycinforearlystagehodgkinlymphomapatientstreatedwithcombinedmodalitytherapydoesincompleteabvdleadtoinferioroutcomes
AT steinerraphaele partialomissionofbleomycinforearlystagehodgkinlymphomapatientstreatedwithcombinedmodalitytherapydoesincompleteabvdleadtoinferioroutcomes
AT nairranjit partialomissionofbleomycinforearlystagehodgkinlymphomapatientstreatedwithcombinedmodalitytherapydoesincompleteabvdleadtoinferioroutcomes
AT stratipaolo partialomissionofbleomycinforearlystagehodgkinlymphomapatientstreatedwithcombinedmodalitytherapydoesincompleteabvdleadtoinferioroutcomes
AT neelapusattvas partialomissionofbleomycinforearlystagehodgkinlymphomapatientstreatedwithcombinedmodalitytherapydoesincompleteabvdleadtoinferioroutcomes
AT nastoupillorettaj partialomissionofbleomycinforearlystagehodgkinlymphomapatientstreatedwithcombinedmodalitytherapydoesincompleteabvdleadtoinferioroutcomes
AT dabajabouthainas partialomissionofbleomycinforearlystagehodgkinlymphomapatientstreatedwithcombinedmodalitytherapydoesincompleteabvdleadtoinferioroutcomes

Ejemplares similares